Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Revvity

< Previous 1 2 Next >
Preliminary Injunction Granted to Enforce Revvity’s Rights and Cloud Software Group’s Obligations Related to Spotfire Software
From Revvity
Via Business Wire
Tickers RVTY
Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group
From Revvity
Via Business Wire
Tickers RVTY
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication
From Revvity
Via Business Wire
Tickers RVTY
Revvity Introduces New Workflow to Accelerate Newborn Sequencing Research
From Revvity
Via Business Wire
Revvity to Present at Upcoming Investor Conferences
From Revvity
Via Business Wire
Tickers RVTY
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions
From Revvity
Via Business Wire
Tickers RVTY
Propelling Diagnostics and Life Sciences Innovation from Early Phase Research to the Clinic: Revvity Showcases Cutting-Edge Solutions at SLAS2024
From Revvity
Via Business Wire
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023
From Revvity
Via Business Wire
Tickers RVTY
Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of Directors
From Revvity
Via Business Wire
Tickers RVTY
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Tickers RVTY
Revvity to Hold Earnings Call on Thursday, February 1, 2024; Provides Update on Financial Performance
From Revvity
Via Business Wire
Tickers RVTY
Revvity to Present at J.P. Morgan Healthcare Conference
From Revvity
Via Business Wire
Tickers RVTY
Revvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCID
From Revvity
Via Business Wire
Revvity to Present at Annual Evercore ISI HealthCONx Conference
From Revvity
Via Business Wire
Tickers RVTY
Revvity Announces Financial Results for the Third Quarter of 2023
From Revvity
Via Business Wire
Tickers RVTY
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Tickers RVTY
Revvity Debuts Inaugural ESG Report
From Revvity
Via Business Wire
Tickers RVTY
Revvity and Element Biosciences Announce Collaboration to Improve Next Generation Sequencing Research Workflow
From Revvity
Via Business Wire
Revvity To Hold Earnings Call on Monday, October 30, 2023
From Revvity
Via Business Wire
Tickers RVTY
Revvity Expands Access to Base Editing Technology With Aim to Accelerate Discovery to Cure
From Revvity
Via Business Wire
Tickers RVTY
Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries
From Revvity
Via Business Wire
Tickers RVTY
Revvity to Present at Upcoming September Investor Conferences
From Revvity
Via Business Wire
Tickers RVTY
Revvity Announces Financial Results for the Second Quarter of 2023
From Revvity
Via Business Wire
Tickers RVTY
Revvity Signals Software and Scitara Expand Strategic Relationship to Accelerate Laboratory Digital Transformation
From Revvity
Via Business Wire
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Tickers RVTY
Revvity Accelerates NGS Library Prep with Introduction of New Fontus Automated Liquid Handling Workstation at 2023 AACC
From Revvity
Via Business Wire
Tickers RVTY
Revvity to Hold Earnings Call on Tuesday, August 1, 2023
From Revvity
Via Business Wire
Tickers RVTY
Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research
From Revvity
Via Business Wire
Tickers RVTY
Revvity’s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System
From Revvity
Via Business Wire
Tickers RVTY
Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development
From Revvity
Via Business Wire
Tickers RVTY
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.